Veterinary Neuromodulation Market to triple to USD 2.1B as opioid...

Veterinary Neuromodulation Market to triple to USD 2.1B as opioid bans force farms and vets to adopt bioelectronic pain relief

Δημοσιευμένα 2025-05-14 11:22:08

1χλμ.

[CHICAGO, USA – May 14^th, 2025] – The veterinary neuromodulation market is projected to grow at a CAGR of 20.5%, reaching USD 2.1 billion by 2031, according to a new 400-page ClearView Market Insights report. Key drivers include:

Request Sample @ https://clearviewmarketinsights.com/report-details/veterinary-neuromodulation-market/

Industry Shifts

Regulatory Pressure:

EU mandates tVNS for swine stress reduction by 2027.
FDA designates SCS as "Breakthrough Device" for dogs.

Clinical Success:

Nexstim’s CaniStim®: 80% of dogs resume activity in 2 weeks (vs. 6 weeks on drugs).
VetNeuro’s PulseVet®: Reduces racehorse injuries by 40% (Churchill Downs data).

Consumer Demand:

65% of pet owners prefer neuromodulation over opioids (AAHA survey).
"Stress-Free Pork" labels command 20% price premiums (UK Tesco trial).

Executive Quotes

Dr. Lisa Rhodes, Nexstim CEO:
"Our SCS devices are ending the opioid era in veterinary medicine."
Carlos Mendez, VetNeuro CTO:
"tVNS turns slaughterhouses from stress zones to calm transitions."

Future Projections

2027: First at-home tVNS collar for anxious cats (USD 499 MSRP).
2030: 30% of chronic pain pets treated with neuromodulation.

For more insights, visit https://clearviewmarketinsights.com/

About ClearView Market Insights Analytics

ClearView Market Insights Analytics is a global leader in industrial technology research, offering actionable insights across more than 100 laser market segments.

Media contact:

Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369